Of note, studies assessing the effects of pharmacologic MR antagonism using spironolactone or eplerenone (27, 28) have shown that MR antagonism prevents liver steatosis in animal models of NASH, reinforcing the role of MR in modulating steatosis development. This evidence concerns the gene NR3C2 and Hepatic steatosis.